Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won’t just fall into your lap. As part of an ongoing series, I’m looking today at 10 measures to show whether Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) makes a great retirement-oriented stock.
Teva stands out from its pharmaceutical peers because of its dual focus on both proprietary and generic drugs. In particular, its ability to make money when its rivals’ drugs go off-patent has brought Teva impressive profits over the years. Below, we’ll revisit how Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) does on our 10-point scale.
The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.
Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.
When scrutinizing a stock, retirees should look for:
Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts’ growth potential, but they do offer greater security.
Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won’t make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock’s share price.
Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won’t fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time — as long as it doesn’t jeopardize the company’s financial health.
With those factors in mind, let’s take a closer look at Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
| Factor | What We Want to See | Actual | Pass or Fail? |
|---|---|---|---|
| Size | Market cap > $10 billion | $34.3 billion | Pass |
| Consistency | Revenue growth > 0% in at least four of past five years | 5 years | Pass |
| Free cash flow growth > 0% in at least four of past five years | 4 years | Pass | |
| Stock stability | Beta < 0.9 | 0.38 | Pass |
| Worst loss in past five years no greater than 20% | (21.2%) | Fail | |
| Valuation | Normalized P/E < 18 | 13.97 | Pass |
| Dividends | Current yield > 2% | 3.1% | Pass |
| 5-year dividend growth > 10% | 21.1% | Pass | |
| Streak of dividend increases >= 10 years | 13 years | Pass | |
| Payout ratio < 75% | 43.6% | Pass | |
| Total score | 9 out of 10 |
Source: S&P Capital IQ. Total score = number of passes.
Since we looked at Teva Pharmaceutical last year, the company has picked up a point, with its free cash flow having returned to its past growth trajectory. But the stock has languished, falling about 10% over the past year.
